Crystal ball time: Looking ahead at T-DM1, Invokana, BG-12
This article was originally published in Scrip
Executive Summary
When it comes to the US FDA, nothing is ever guaranteed – as Novo Nordisk learned the hard way over the weekend after getting slapped with an icy-cold mid-winter complete response letter (CRL) for its investigational Type I and Type II diabetes treatments Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart).